Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Penn Study Details Dimmer Switch for Regulating Cell's Read of DNA Code

Published: Wednesday, January 09, 2013
Last Updated: Wednesday, January 09, 2013
Bookmark and Share
Findings have implications for cancer and neurological treatments.

Epigenetics - the science of how gene activity can be altered without changes in the genetic code - plays a critical role in every aspect of life, from the differentiation of stem cells to the regulation of metabolism and growth of cancer cells. Epigenetic factors act by reworking the structure in which genes reside, called chromatin. Inside chromatin, DNA is wound around proteins called histones. Several new cancer treatments interfere with the function of enzymes that chemically mark the histones to alter the readout of the DNA code and ramp the expression of genes up or down, as if with a dimmer switch. Enzymes called histone deacetylases (HDACs) erase the mark and shut off gene expression.

A team led by Mitchell A. Lazar, M.D., Ph.D., director of the Institute for Diabetes, Obesity, and Metabolism at the Perelman School of Medicine, University of Pennsylvania, has been studying HDAC3 for several years. They discovered that the enzyme activity of HDAC3 requires interaction with a specific region on another protein, which they dubbed the Deacetylase Activating Domain or "DAD.” This “nuts and bolts” discovery on the epigenetic control of a person’s genome has implications for cancer and neurological treatments.

This domain is found only in proteins that are nuclear receptor corepressors (NCoR1 and NCOR2), which assist receptor proteins in the nucleus to downregulate gene expression.

The team showed that HDAC3 enzyme activity is undetectable in mice bearing mutations in the DAD of both NCOR1 and NCOR2, also called SMRT, despite having normal levels of HDAC3 protein. The findings were published this week in Nature Structural & Molecular Biology.

HDAC3 is required for normal mouse development and tissue-specific functions. In cell culture studies, the HDAC3 protein itself has minimal enzyme activity but gains its histone-deacetylation function from stable association with the DAD.

“We developed a unique mouse model to directly test whether HDAC3 absolutely requires NCOR1 and/or SMRT to be activated,” says Lazar. “The answer is yes.” The results clearly show that, although tissue levels of HDAC3 are normal in this mouse model, the protein does not have detectable enzyme activity in embryos and various tissues of the engineered mice.

Surprisingly, the engineered mice are born and live to adulthood, whereas genetic absence of HDAC3 is lethal to the mice before they are born.  This suggests that HDAC3 may have a deacetylase-independent function which, Lazar says, “is potentially of major importance, because HDAC inhibitors are currently used clinically to treat cancer, and are in clinical development for neurological illnesses and other disorders.  We are working hard in the lab to sort this out.”

Co-authors are Seo-Hee You, Hee-Woong Lim, Zheng Sun, Molly Broache, and Kyoung-Jae Won, all from Penn. The research was supported in part by the National Institute of Diabetes, and Digestive and Kidney Diseases (R37DK43806) and a Mentor Based Fellowship from the American Diabetes Association.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First Atlas of Body Clock Gene Expression in Mammals Informs Timing of Drug Delivery
Penn Medicine study has implications for 100 top-selling US drugs, half of which target daily-oscillating genes.
Thursday, October 30, 2014
Ovarian Cancer Oncogene Found in "Junk DNA"
The study is published online in this week in Cancer Cell.
Wednesday, September 10, 2014
Researchers Identify Four New Genetic Risk Factors for Testicular Cancer
Large, first-of-its-kind study finds genomic regions associated with higher risk.
Wednesday, May 15, 2013
T-Cell Therapy Eradicates an Aggressive Leukemia in Two Children
CHOP/Penn Medicine oncology team reports complete remission in pediatric ALL patients.
Tuesday, March 26, 2013
Changes to DNA On-Off Switches Affect Cells' Ability to Repair Breaks
Many proteins are involved in everyday DNA repair, but if they are mutated, the repair system breaks down and cancer can occur.
Wednesday, February 06, 2013
Penn Study on Silencing of Tumor Suppressor Gene Suggests New Target for Lymphoma
Professors from the Perelman School of Medicine at the University of Pennsylvania, and their colleagues, found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain (IL-2R?). The results suggest news targets for lymphoma and other types of cancer.
Monday, December 12, 2011
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!